| 15.1 0.005 (0.03%) | 07-31 10:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.3 | 1-year : | 21.37 |
| Resists | First : | 15.67 | Second : | 18.3 |
| Pivot price | 15.24 |
|||
| Supports | First : | 14.86 | Second : | 14.36 |
| MAs | MA(5) : | 15.22 |
MA(20) : | 15.13  |
| MA(100) : | 14.13 |
MA(250) : | 14.43 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 29.7 |
D(3) : | 49 |
| RSI | RSI(14): 52.5 |
|||
| 52-week | High : | 16.73 | Low : | 12.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INMD ] has closed above bottom band by 20.0%. Bollinger Bands are 38.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.17 - 15.25 | 15.25 - 15.32 |
| Low: | 14.74 - 14.84 | 14.84 - 14.93 |
| Close: | 14.94 - 15.1 | 15.1 - 15.23 |
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Thu, 30 Jul 2026
InMode Ltd. (NASDAQ: INMD) director receives 2,000 RSU equity award - Stock Titan
Thu, 30 Jul 2026
InMode Ltd. (INMD) grants director 2,000 RSU equity shares - Stock Titan
Thu, 30 Jul 2026
InMode Ltd. (INMD) awards director Ron Hadar 2,000 RSUs - Stock Titan
Thu, 30 Jul 2026
INMD|Inmode Ltd|Price:15.160|Chg%:-0.310 - TradingKey
Wed, 29 Jul 2026
Altshuler Shaham Ltd Has $1.64 Million Stake in InMode Ltd. $INMD - MarketBeat
Mon, 27 Jul 2026
InMode Ltd. $INMD Shares Bought by Steel Partners Holdings L.P. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 57 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 13.1 (%) |
| Held by Institutions | 58 (%) |
| Shares Short | 2,990 (K) |
| Shares Short P.Month | 3,280 (K) |
| EPS | 1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.77 |
| Profit Margin | 23.2 % |
| Operating Margin | 12.2 % |
| Return on Assets (ttm) | 6.8 % |
| Return on Equity (ttm) | 13.6 % |
| Qtrly Rev. Growth | 5.3 % |
| Gross Profit (p.s.) | 5.07 |
| Sales Per Share | 6.51 |
| EBITDA (p.s.) | 1.4 |
| Qtrly Earnings Growth | -30.8 % |
| Operating Cash Flow | 87 (M) |
| Levered Free Cash Flow | 44 (M) |
| PE Ratio | 11.13 |
| PEG Ratio | 0.8 |
| Price to Book value | 1.39 |
| Price to Sales | 2.3 |
| Price to Cash Flow | 9.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|